Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 1027
Publisher
MDPI AG
Online
2020-04-23
DOI
10.3390/cancers12041027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
- (2019) Bastian Schilling et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
- (2019) Andrea Forschner et al. Journal for ImmunoTherapy of Cancer
- Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
- (2019) Mehmet Asim Bilen et al. BMC CANCER
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- LBA67Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)
- (2019) D Schadendorf et al. ANNALS OF ONCOLOGY
- Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice
- (2019) Anna M. Czarnecka et al. Targeted Oncology
- Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
- (2019) Justin C. Moser et al. Cancer Medicine
- Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
- (2019) Johanna Veldman et al. CANCER TREATMENT REVIEWS
- A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma
- (2019) Margreet G. Franken et al. EUROPEAN JOURNAL OF CANCER
- S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
- (2018) Nikolaus B Wagner et al. BRITISH JOURNAL OF CANCER
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
- (2018) Curtis H. Kugel et al. CLINICAL CANCER RESEARCH
- Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
- (2018) Yingcheng Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
- (2018) Antonino Grassadonia et al. Journal of Clinical Medicine
- Sequencing Treatment in BRAFV600 Mutant Melanoma
- (2017) Douglas B. Johnson et al. JOURNAL OF IMMUNOTHERAPY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- IL-37b suppresses T cell priming by modulating dendritic cell maturation and cytokine production via dampening ERK/NF-κB/S6K signalings
- (2015) Wantong Wu et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
- (2013) Ana B. del Campo et al. INTERNATIONAL JOURNAL OF CANCER
- Functional characterization of a STAT3-dependent dendritic cell-derived CD14+cell population arising upon IL-10-driven maturation
- (2013) Jelle J. Lindenberg et al. OncoImmunology
- Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
- (2012) B Weide et al. BRITISH JOURNAL OF CANCER
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now